NCT01014117View on ClinicalTrials.gov

Effect of SRT2104 on Endotoxin-induced Inflammation

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 9, 2009

Primary Completion Date

May 10, 2010

Study Completion Date

May 10, 2010

Conditions
Sepsis
Interventions
DRUG

Placebo

Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

DRUG

SRT2104

SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.

Trial Locations (1)

1105 AZ

GSK Investigational Site, Amsterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01014117 - Effect of SRT2104 on Endotoxin-induced Inflammation | Biotech Hunter | Biotech Hunter